The VP1u Receptor Restricts Parvovirus B19 Uptake to Permissive Erythroid Cells.
Parvovirus B19 (B19V) is a small non-enveloped virus and known as the causative agent for the mild childhood diseaseerythema infectiosum. B19V has an extraordinary narrow tissue tropism, showing only productive infection in erythroid precursor cells in the bone marrow. We recently found that the viral protein 1 unique region (VP1u) contains an N-terminal receptor-binding domain (RBD), which mediates the uptake of the virus into cells of the erythroid lineage. To further investigate the role of the RBD in connection with a B19V-unrelated capsid, we chemically coupled the VP1u of B19V to the bacteriophage MS2 capsid and tested the internalization capacity of the bioconjugate on permissive cells. In comparison, we studied the cellular uptake and infection of B19V along the erythroid differentiation. The results showed that the MS2-VP1u bioconjugate mimicked the specific internalization of the native B19V into erythroid precursor cells, which further coincides with the restricted infection profile. The successful mimicry of B19V uptake demonstrates that the RBD in the VP1u is sufficient for the endocytosis of the viral capsid. Furthermore, the recombinant VP1u competed with B19V uptake into permissive cells, thus excluding a significant alternative uptake mechanism by other receptors. Strikingly, the VP1u receptor appeared to be expressed only on erythropoietin-dependent erythroid differentiation stages that also provide the necessary intracellular factors for a productive infection. Taken together, these findings suggest that the VP1u binds to a yet-unknown erythroid-specific cellular receptor and thus restricts the virus entry to permissive cells.
Department of Chemistry and Biochemistry, University of Bern, Bern 3012, Switzerland. remo.leisi@dcb.unibe.ch.
Remo
R
Leisi
Department of Chemistry and Biochemistry, University of Bern, Bern 3012, Switzerland. marcus.vonnordheim@dcb.unibe.ch.
Marcus
M
Von Nordheim
Department of Chemistry and Biochemistry, University of Bern, Bern 3012, Switzerland. carlos.ros@dcb.unibe.ch.|CSL Behring AG, Bern 3014, Switzerland. carlos.ros@dcb.unibe.ch.
Carlos
C
Ros
Department of Chemistry and Biochemistry, University of Bern, Bern 3012, Switzerland. christoph.kempf@dcb.unibe.ch.|CSL Behring AG, Bern 3014, Switzerland. christoph.kempf@dcb.unibe.ch.
Christoph
C
Kempf
MS2 bioconjugation; VP1u; VP1u receptor; erythropoiesis; parvovirus B19; tropism; virus entry; virus mimicry
Cytotherapy. 2015 Oct;17(10):1472-84
26164068
PLoS Biol. 2010 Sep 21;8(9):null
20877475
J Virol. 2008 Dec;82(23):11784-91
18815302
J Virol. 1993 Jun;67(6):3004-9
7684458
Am J Hematol. 1976;1(4):453-8
1008057
Br J Haematol. 1992 Oct;82(2):302-9
1419811
J Cell Physiol. 1988 Oct;137(1):65-74
2459142
Bioconjug Chem. 1995 Sep-Oct;6(5):587-95
8974458
Blood. 1997 Dec 1;90(11):4384-93
9373249
Bioconjug Chem. 2015 Sep 16;26(9):1923-30
26240997
Nature. 1990 May 3;345(6270):36-41
2330049
J Virol. 2013 Dec;87(24):13161-7
24067971
Blood. 2003 Dec 1;102(12):3927-33
12907437
Blood. 1990 Feb 1;75(3):603-10
2404522
PLoS One. 2010 Mar 02;5(3):e9496
20209110
Virology. 2014 May;456-457:364-9
24889255
J Virol. 1999 Mar;73(3):1974-9
9971777
Blood. 2008 Aug 1;112(3):470-8
18650462
Future Virol. 2015;10(2):155-167
26097496
J Virol. 2010 Nov;84(22):11737-46
20826697
J Virol. 1987 Aug;61(8):2627-30
3599184
Science. 1990 Apr 20;248(4953):378-81
2326648
Nat Methods. 2012 Jul;9(7):671-5
22930834
Protein Sci. 2009 Aug;18(8):1653-61
19521994
Nucleic Acids Res. 2001 Nov 15;29(22):E113
11713333
Vaccine. 2013 Aug 20;31(37):3872-8
23827313
Rev Fr Transfus Immunohematol. 1987 Dec;30(5):699-708
3330858
J Virol. 2001 May;75(9):4110-6
11287560
J Mol Biol. 1996 Feb 23;256(2):330-9
8594200
Clin Microbiol Rev. 2002 Jul;15(3):485-505
12097253
Blood. 1993 Oct 15;82(8):2340-52
8400286
Exp Hematol. 2016 Aug;44(8):653-63
26646992
J Virol. 2008 Mar;82(5):2470-6
18160440
J Virol. 1986 Nov;60(2):548-57
3021988
Virology. 1995 Jan 10;206(1):626-32
7530397
Viruses. 2016 Feb 24;8(3):61
26927158
Cell. 1995 Oct 6;83(1):59-67
7553874
Mol Pharm. 2013 Jan 7;10(1):59-68
23110441
Blood. 1995 Nov 15;86(10):3745-53
7579341
Science. 1993 Oct 1;262(5130):114-7
8211117
J Virol. 2010 Dec;84(23):12385-96
20861249
Blood. 2005 Nov 15;106(10 ):3449-56
16076874
J Virol Methods. 2013 Oct;193(1):215-25
23764418
J Clin Invest. 1989 Oct;84(4):1114-23
2551923
N Engl J Med. 1994 Apr 28;330(17):1192-6
8139629
J Gen Virol. 1993 Apr;74 ( Pt 4):541-8
7682249
PLoS One. 2016 Feb 04;11(2):e0148547
26845771